SCHEMBL4215069

SCHEMBL4215069

O=c1[nH]cnc2c1sc1cc(Cl)ccc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
PIM1 P11309 12/20 0.51
PIM2 Q9P1W9 8/20 0.51
CLK4 Q9HAZ1 5/20 0.51
GSK3A P49840 4/20 0.51
GSK3B P49841 4/20 0.51
DYRK1A Q13627 4/20 0.51
PIM3 Q86V86 4/20 0.51
IGF1R P08069 3/20 0.51
CLK2 P49760 3/20 0.51
DAPK3 O43293 3/20 0.51
PRKD3 O94806 3/20 0.51
CDC7 O00311 2/20 0.51
DYRK3 O43781 2/20 0.51
CSNK2A1 P68400 2/20 0.51
PKN2 Q16513 2/20 0.51
AURKA O14965 2/20 0.51
MAP4K4 O95819 2/20 0.51
RET P07949 2/20 0.51
PRKX P51817 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4213078 0.88 PIM1 (0.59) ALDH1A1PIM1PIM2CLK4GSK3A
SCHEMBL4207983 0.82 PIM1 (0.49) ALDH1A1PIM1PIM2CLK4GSK3A
SCHEMBL4207625 0.82 PARP1 (0.49) ALDH1A1PIM1PIM2CLK4GSK3A
SCHEMBL4208127 0.79 LIMK1 (0.59) PIM1PIM2CLK4GSK3AGSK3B
SCHEMBL4208864 0.78 KRAS (0.51) PIM1PIM2CLK4GSK3AGSK3B
SCHEMBL4208101 0.75 PARP1 (0.41) PIM1PIM2CLK4GSK3AGSK3B
SCHEMBL2302798 0.75 KDM4A (0.51) ALDH1A1PIM1PIM2CLK4GSK3A
SCHEMBL4207979 0.73 PARP1 (0.53) ALDH1A1PIM1PIM2CLK4GSK3A
SCHEMBL4219756 0.73 PIM1 (0.53) ALDH1A1PIM1PIM2CLK4GSK3A
SCHEMBL31564822 0.72 PDPK1 (0.50) ALDH1A1PIM1PIM2CLK4GSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030196-A1 PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS ABBOTT LABORATORIES (US) 2009-01-29 US claimed
US-20090030196-A1 PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS ABBOTT LABORATORIES (US) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030196-A1 PIM KINASE INHIBITORS AS CANCER CHEMOTHERAPEUTICS PIM1, PIM3, PIM2 ALDH1A1 1668/4885PIM1 1/4885PIM2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.